Ruo Yu Chen
Nessuna posizione attualmente
Patrimonio netto: - $ in data 31/05/2024
Profilo
Ruo Yu Chen is currently the Executive Director at Continent Pharmaceutical Inc. and Beijing Continent Pharmaceutical Co., Ltd.
She is also the Supervisor at GNI-EPS Pharmaceuticals, inc., Finance Controller at Cullgen, Inc., and Supervisor at Cullgen Shanghai, Inc. In addition, she holds the position of Chief Financial Officer at Gyre Therapeutics, Inc. starting in 2023 and Senior Vice President-Finance at GNI USA, Inc. starting in 2021.
Previously, she worked as the Director-Finance & Accounting at GNI Group Ltd.
from 2014 to 2021 and as the Manager-Internal Audit Division at Protiviti LLC.
Ms. Chen completed her undergraduate degree at Nankai University in 1992 and her graduate degree at the Graduate School of Economics Kyoto University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
-.--% | 19/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Ruo Yu Chen
Società | Posizione | Inizio |
---|---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Direttore/Membro del Consiglio | 18/07/2018 |
GNI USA, Inc.
GNI USA, Inc. BiotechnologyHealth Technology GNI USA, Inc. engages in therapeutic pharmaceutical products development and production. The company was founded in 2001 and is headquartered in San Jose, CA. | Corporate Officer/Principal | 01/01/2021 |
Cullgen, Inc.
Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | Comptroller/Controller/Auditor | - |
Cullgen Shanghai, Inc. | Direttore/Membro del Consiglio | - |
GNI-EPS Pharmaceuticals, inc. | Direttore/Membro del Consiglio | - |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Direttore/Membro del Consiglio | 01/01/2018 |
Precedenti posizioni note di Ruo Yu Chen
Società | Posizione | Fine |
---|---|---|
GNI GROUP LTD. | Comptroller/Controller/Auditor | 01/01/2021 |
Protiviti LLC
Protiviti LLC Miscellaneous Commercial ServicesCommercial Services Part of Robert Half, Inc., Protiviti LLC is a business consulting firm that provides IT consulting, risk and compliance, digital transformation, and internal audit services. The company is based in Tokyo, Japan. Protiviti also offers a platform for alumni to connect, reminisce, and stay in touch, as well as to introduce, employ, and mentor fellow alumni. | Comptroller/Controller/Auditor | - |
Formazione di Ruo Yu Chen
Nankai University | Undergraduate Degree |
Graduate School of Economics Kyoto University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
GNI GROUP LTD. | Health Technology |
Aziende private | 7 |
---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
Protiviti LLC
Protiviti LLC Miscellaneous Commercial ServicesCommercial Services Part of Robert Half, Inc., Protiviti LLC is a business consulting firm that provides IT consulting, risk and compliance, digital transformation, and internal audit services. The company is based in Tokyo, Japan. Protiviti also offers a platform for alumni to connect, reminisce, and stay in touch, as well as to introduce, employ, and mentor fellow alumni. | Commercial Services |
GNI USA, Inc.
GNI USA, Inc. BiotechnologyHealth Technology GNI USA, Inc. engages in therapeutic pharmaceutical products development and production. The company was founded in 2001 and is headquartered in San Jose, CA. | Health Technology |
Cullgen, Inc.
Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Cullgen, Inc. operates as a biopharmaceutical company. It develops chemical entities for the treatment of diseases lacking effective therapeutic approaches. The company was founded in 2018 and is headquartered in San Diego, CA. | Health Technology |
Cullgen Shanghai, Inc. | |
GNI-EPS Pharmaceuticals, inc. | |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
- Borsa valori
- Insiders
- Ruo Yu Chen